cGMP signaling in cardiovascular diseases: Linking genotype and phenotype

Tan An Dang, Heribert Schunkert, Thorsten Kessler

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Cyclic guanosine 3',5'-monophosphate (cGMP) is the key second messenger molecule in nitric oxide signaling. Its rapid generation and fate, but also its role in mediating acute cellular functions has been extensively studied. In the past years, genetic studies suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, for example, coronary artery disease and myocardial infarction. Here, we review the role of cGMP in atherosclerosis and other cardiovascular diseases and discuss recent genetic findings and identified mechanisms. Finally, we highlight open questions and promising research topics.

Original languageEnglish
Pages (from-to)516-525
Number of pages10
JournalJournal of Cardiovascular Pharmacology
Volume75
Issue number6
DOIs
StatePublished - 2020

Keywords

  • CGMP
  • Cardiovascular diseases
  • Coronary artery disease
  • Genetics
  • Genome-wide association studies
  • Myocardial infarction

Fingerprint

Dive into the research topics of 'cGMP signaling in cardiovascular diseases: Linking genotype and phenotype'. Together they form a unique fingerprint.

Cite this